Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | HTR1A | P08908 | 5/20 | 0.68 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.68 |
| ▸ | HTR1D | P28221 | 4/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.68 |
| ▸ | HTR2B | P41595 | 3/20 | 0.68 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.68 |
| ▸ | HTR1B | P28222 | 3/20 | 0.68 |
| ▸ | HTR2A | P28223 | 3/20 | 0.68 |
| ▸ | HTR2C | P28335 | 3/20 | 0.68 |
| ▸ | HTR7 | P34969 | 3/20 | 0.68 |
| ▸ | HTR6 | P50406 | 3/20 | 0.68 |
| ▸ | HTR1E | P28566 | 2/20 | 0.68 |
| ▸ | HTR5A | P47898 | 2/20 | 0.68 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.68 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.68 |
| ▸ | HTR3B | O95264 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | HTR1F | P30939 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227242 | 0.91 | KMT2A (0.69) | KMT2AHTR1AMTNR1AHTR1DCYP2D6 | |
| SCHEMBL4075720 | 0.89 | KMT2A (0.72) | KMT2AHTR1AMTNR1AHTR1DCYP2D6 | |
| SCHEMBL5433172 | 0.88 | KMT2A (0.67) | KMT2AHTR1AMTNR1AHTR1DCYP2D6 | |
| SCHEMBL5144423 | 0.88 | KMT2A (0.74) | KMT2AHTR1AMTNR1AHTR1DCYP2D6 | |
| SCHEMBL16058705 | 0.86 | KMT2A (0.69) | KMT2AHTR1AMTNR1AHTR1DCYP2D6 | |
| SCHEMBL28414663 | 0.86 | KMT2A (0.69) | KMT2AHTR1AMTNR1AHTR1DCYP2D6 | |
| SCHEMBL5146979 | 0.84 | KMT2A (0.66) | KMT2AHTR1AMTNR1AHTR1DCYP2D6 | |
| SCHEMBL5085568 | 0.83 | KMT2A (0.65) | KMT2AHTR1AMTNR1AHTR1DCYP2D6 | |
| SCHEMBL5085972 | 0.83 | KMT2A (0.65) | KMT2AHTR1AMTNR1AHTR1DCYP2D6 | |
| SCHEMBL5144364 | 0.83 | KMT2A (0.65) | KMT2AHTR1AMTNR1AHTR1DCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4706758-A2 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116854760-A | Application of ganoderma lucidum lanolin alkane type triterpene compound in preparation of CYP metabolic enzyme inhibitor | 南昌大学第一附属医院 | 2023-10-10 | — | — | CN | disclosed |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-3884935-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-114404588-A | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-114340631-A | Combination for reducing serum phosphate in a patient | 阿德利克斯股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3972599-A1 | COMBINATION FOR LOWERING SERUM PHOSPHATE IN A PATIENT | Ardelyx, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-2197414-B1 | TOPICAL FORMULATION FOR THE TREATMENT OF CELLULITE | FARM PROCEMSA S P A (IT) | 2017-11-15 | — | — | EP | disclosed |
| EP-2405912-A2 | METHOD OF DISEASE-INDUCED AND RECEPTOR-MEDIATED STEM CELL NEUROPROTECTION | University Of South Florida (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20120009271-A1 | METHOD OF DISEASE-INDUCED AND RECEPTOR-MEDIATED STEM CELL NEUROPROTECTION | MEDICAL COLLEGE OF GEORGIA (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110280962-A1 | METALLIZATION DEVICE AND METHOD | Via Hodesia, 6 (IT) | 2011-11-17 | — | — | US | disclosed |
| WO-2010105144-A2 | METHOD OF DISEASE-INDUCED AND RECEPTOR-MEDIATED STEM CELL NEUROPROTECTION | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-09-16 | — | — | WO | disclosed |
| EP-2197414-A1 | TOPICAL FORMULATION FOR THE TREATMENT OF CELLULITE | Chronolife S.r.l. (IT) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009040851-A1 | TOPICAL FORMULATION FOR THE TREATMENT OF CELLULITE | CHRONOLIFE S.R.L. (IT) | 2009-04-02 | — | — | WO | disclosed |
| US-20070218023-A1 | Uses of melatonin in skin | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE | 2007-09-20 | — | — | US | disclosed |
| WO-2003039677-A2 | COVALENT CONJUGATES OF BIOLOGICALLY-ACTIVE COMPOUNDS WITH AMINO ACIDS AND AMINO ACID DERIVATIVES FOR TARGETING TO PHYSIOLOGICALLY-PROTECTED SITES | ENZREL, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| EP-0820768-A2 | New melatonin derivatives as anti-free-radical agent and compositions comprising the same | L'OREAL (FR) | 1998-01-28 | — | — | EP | disclosed |
| EP-0820767-A2 | Use of melatonin derivatives for skin depigmentation and compositions comprising the same | L'OREAL (FR) | 1998-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | KMT2A 4666/4885HTR1A 2902/4885MTNR1A 3262/4885 |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | SLC34A3, SLC34A2, SLC34A1 | KMT2A 4666/4885HTR1A 2902/4885MTNR1A 3262/4885 |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | KMT2A 4139/4885HTR1A 4365/4885MTNR1A 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.